Summary The concentrations of cathepsin D (Cath D), urokinase (uPA) and two plasminogen activator inhibitors (PAI-I and PAI-2) were analysed in the cytosols of 130 human mammary tumours (43 benign tumours and 87 primary and unilateral breast carcinomas). uPA, PAI-i and PAI-2 levels were measured by antigenic immunoassays and Cath D by immunoradiometric assay. The median levels of the four parameters were significantly higher in the malignant tumours than in the benign ones. Cath D and uPA increases were 4-fold and 5-fold respectively. PAI-I and PAI-2 increases were much more important, 74-fold and 29-fold respectively. In malignant tumours, median levels of Cath D and uPA did not vary according to classical prognostic factors (histologic grade, presence or absence of axillary lymph nodes, steroid receptors, UICC stage, tumour size, age, and menopausal status). However, PAI-I decreased in ER+ and PR+ tumours and PAI-2 increased in menopausal women's tumours. When Cath D, uPA, PAI-I and PAI-2 levels in malignant tumours were compared, positive correlations were found for all combinations. The implication of plasminogen activator inhibitors in the phenomenon was surprising and merits further investigation using tools other than global antigen measurements in tumours.
Proteases play a role in metastatic dissemination. They contribute to basement membrane and connective tissue degradation, allowing vascular endothelial crossover (for review: Mullins & Rohrlich, 1983; Tryggvason et al., 1987; Moscatelli & Rifkin, 1988; Gottesman, 1990) . Diverse enzymes are produced in abundance by malignant cells and are implicated in tumour cell invasion: collagenases (for review : Liotta et al., 1982; Stetler-Stevenson, 1990 ); stromelysin (McDonnel & Matrisian, 1990) ; cathepsin B (Sloane et al., 1984; ; cathepsin D (Maguchi et al., 1988; Rochefort et al., 1990) ; heparanase (Nakajima et al., 1987) ; urokinase type plasminogen activator (for review: Dano et al., 1985;  Markus, 1988; Testa & Quigley, 1990) . Their proteolytic activities are often concentrated in the pericellular environment or cell surface bound (Zucker et al., 1985) .
Among these enzymes, urokinase (uPA) has been extensively studied. uPA is a serine protease that transforms plasminogen into plasmin which is active on a large number of substrates. It can degrade basement membrane components (Liotta et al., 1981) and can activate type IV procollagenase (Paranjpe et al., 1980; O'Grady et al., 1981) . uPA can by itself degrade fibronectin (Gold et al., 1989) . Inhibition of uPA using anti-urokinase antibodies has shown the importance of uPA in tumour invasion (Ossowski & Reich, 1983) . The inhibition of uPA activity prevents laminin degradation (Boyd et al., 1989) and invasion of amniotic membrane (Mignatti et al., 1986; Yagel et al., 1989; Tsuboi & Rifkin, 1990) and of extracellular matrix (Meissauer et al., 1991) . Moreover, transfection of uPA gene into H-ras-transformed fibroblasts, mouse L cells, and murine melanoma cells enhances invasion and metastasis of these cells (Axelrod et al., 1989; Cajot et al., 1989; Yu & Schultz, 1990) . During the metastatic process, uPA is especially potent in mesenchymal infiltration and intravasation by tumour cells (Ossowski, 1988a) . uPA bound to membrane receptors is more active than free uPA in matrix degradation (Ossowski, 1988b; Hearing et al., 1988; Schlechte et al., 1989) . uPA activity is controlled by several specific inhibitors, PAI-1, PAI-2, PAI-3, protease nexin (for review : Hart & Rehemtulla, 1988) . There are few studies on these inhibitors in malignant tissues, even though they have been detected in variable amounts in several cancer cell lines: bladder, lung, kidney, stomach (Naito et al., 1981) ; breast, uterus, lymphoma, epidermoid carcinoma (Cajot et al., 1986) ; neuroblastoma (Benjamin et al., 1989) . Other cancer cell lines are completely devoid of plasminogen activator inhibitors (Quax et al., 1990 (Maguchi et al., 1988; Capony et al., 1989; Rochefort et al., 1989) . Cath D in conditioned media from certain cell lines can degrade extracellular matrix (Briozzo et al., 1988) .
uPA and Cath D have been independently implicated in malignant progression, but until a recent report by Duffy et al. (1991) , no studies have been made on detection of both proteases in the same tumours. In addition, since little is known of PAIs in tumours, we assayed in 43 benign and 87 malignant tumours, the concomitant production of uPA, Cath D, PAI-I and PAI-2. In the malignant population, they were studied as a function of clinical, histological and biochemical factors. Correlation between Cath D, uPA, PAI-I, PAI-2 in benign and malignant tumours In benign tumours, Cath D and uPA concentrations were significantly and linearly correlated (rs = 0.583, P = 0.00011; rp = 0.486, P = 0.0016). Due to the absence of PAI-l and PAI-2 in the majority of benign tumours, no correlation could be found.
Patients and methods

Patients
In malignant tumours, Cath D and uPA concentrations were significantly, but nonlinearly correlated (Table III) . They were also significantly correlated with concentrations of PAI-I and PAI-2. Cath D was strongly linearly correlated with PAI-I and nonlinearly correlated with PAI-2. uPA was nonlinearly correlated with PAI-I and PAI-2. There was a clear linear correlation between PAI-I and PAI-2. High levels of cytosolic uPA (Duffy et al., 1990; Janicke et al., 1990) and Cath D (Spyratos et al., 1989; Tandon et al., 1989; Thorpe et al., 1989; Romain et al., 1990; Duffy et al., 1991) However their results differ from ours in that they found no correlation between urokinase and PAI-i concentrations. In addition, the increase that they found for PAI-I was small (about 10-fold) compared to the 74-fold increase that we found in malignant over benign tumours. This discrepancy may be due to different buffers and anti-urokinase antibodies used.
The very high PAI-I and PAI-2 increases that occurred with malignancy may counteract urokinase-mediated tissue degradation by tumour cells. In vitro studies have shown that PAI-I and PAI-2 can inhibit plasminogen-dependent extracellular matrix degradation by colon carcinoma cells (Cajot et al., 1990; Baker et al., 1990) . However, the function of these inhibitors in malignancy is puzzling. Maybe they have an activity other than that of inhibiting PAs. GdNPF (gliaderived neurite promoting factor) which inhibits PAs, also regulates the migration of neuronal cells (Gloor et al., 1986 exist for PAI, they could promote tumour cell invasiveness.
Since our technique measured global enzyme and inhibitor levels in cytosols of pulverised tumours, we can ask the question about the tissue compartment responsible for their production. uPA, Cath D and PAIs have been found in plasma (Saito et al., 1990; Freiss et al., 1988; Kruithof et al., 1987) , and in many types of normal cells (Bernik et al., 1981; Jaffe, 1987; Chapman et al., 1982; Bergman et al., 1986; Keski-Oja et al., 1988; Wilson et al., 1987; Tissot et al., 1984; Wohlwend et al., 1987) . However, we can consider that the tumour cells are the major producer. Saito et al. (1990) have shown that the plasmatic concentration of uPA did not vary between patients with ovarian or uterine benign and malignant tumours. By immunohistochemistry, Janicke et al. (1990) and Costantini et al. (1991) have found uPA in the cytoplasma and the plasma membrane of breast tumour cells. For Cath D an immunohistochemistry study of benign and malignant breast tumours has shown that procathepsin D staining was more intense in malignant cells than in benign mastopathies (Garcia et al., 1987) . The distribution of Cath D in human breast appears to be relatively specific for mammary epithelial cells and to be associated with tumour development (Garcia et al., 1984; Garcia et al., 1986) . Besides, in culture, uPA, Cath D, and PAI-I are produced by many breast carcinoma cell lines (Tissot et al., 1984; Cajot et al., 1986; Quax et al., 1990; Briozzo et al., 1988) . Moreover, Costantini et al. (1991) have observed PAI-I in breast tumour cells using immunohistochemical technique. To our knowledge PAI-2 has not been reported in breast carcinoma cell but it is produced by other carcinoma cell lines (Schleef et al., 1988; Heidtmann et al., 1989; George et al., 1990) .
Further studies on the concomitant production of proteases and anti-proteases in malignant tumours should shed a light on their role in matrix degradation. METHLIN, G. (1984) 
